Goldman Small Cap Research

08/24/2023

AI stocks are the hottest segment of the market and for good reason. A new report is out today on an under the radar AI firm abt to surge higher as well. Sybleu (Ticker: SYBE) is an AI-driven drug discovery firm in the lucrative vet health market. This industry segment has peers that boast huge valuations ranging from 27x - 100x revenue---and it looks like SYBE is on the same path as it reaches a series of milestones in the coming months. Investors have an insatiable appetite for these stocks and continue to raise hundreds of millions for them. That is why we believe SYBE could join the party by year-end.

Emerging AI-Driven Biotech Sybleu, Inc. (OTC:SYBE) offers competitive advantages and upcoming milestones in the stock market's top-followed and funded segment, AI, prompting a potential surge in the s

08/17/2023

PUR Biologics, the primary medtech subsidiary of HippoFi, Inc. (Ticker: ORHB) is hitting the ball out of the park. In just the past few months, the company had its biologics products used in spinal surgeries for bone regeneration approved for use in the entire VA health network---that's 171 medical centers and 1,113 outpatient sites serving millions of veterans. Plus, military bases. ORHB has also signed a deal to join forces w/an industry giant, introduced new products, and was awarded 2 new breakthrough patents. The stock appears to be a great entry point as the outcomes of these events should result in major price gains.

In what may be the best kept secret on Wall Street, emerging MedTech Firm HippoFi, Inc. (OTC:ORHB) is experiencing unprecedented sales growth. And that's just part of this innovator's story.

08/17/2023

New report on award-winning smart gym equip maker and digital health services co. Interactive Strength, Inc. d/b/a FORME (NASDAQ: TRNR). Co. just signed an LOI for an acquisition that we believe is transformative for TRNR. It will dramatically accelerate high rev growth/profit. Thus, the deal could lead to major stock gains ahead. TRNR closed @ $1.23, trades only 0.7x sales--artificially low valuation. Now a great entry point. Our target is $4.15, and reflects a reasonable 3x 2024E sales.

Interactive Strength, Inc. (NASDAQ: TRNR) d/b/a FORME is about to make a profound change in its business that will prompt major growth, accelerate profit, and drive the artificially low valuation subs

08/14/2023

We have published new report out on The Healing Company (Ticker: HLCO), the next health and wellness unicorn. HLCO has a strong relationship with Deepak Chopra, who is the Chief Scientific Officer. The company also owns and operates Chopra Global which boasts a huge following, especially on social media. There are a series of acq deals ahead & a $150M M&A credit facility to draw down on which are poised to drive major sales growth. Plus, a NASDAQ uplisting in the cards. We currently have a $9 tgt price.

Leveraging a $150M M&A-targeted credit facility, and a core relationship with Deepak Chopra, integrated health firm The Healing Company, Inc. (OTCQB: HLCO) is poised to record exponential revenue grow

05/05/2023

New report on a company undergoing a major transformation--driving annual rev growth from $162M in 2022 to $913M in 2023, with $0.30 in adjusted EPS. Muscle Maker Inc. (NASDAQ:GRIL) is fast becoming a major player in the global food supply chain, with 2 distinct business lines. Our 6-9 month conservative target is 3x recent prices, with more potential upside in the cards. Given its rapid transformation, and huge growth, GRIL could be the most talked about play on NASDAQ this year.

Muscle Maker, Inc. (NASDAQ: GRIL) is set to grow revenue from $162M in 2022 to over $1B in 2024, with a substantial rise in adjusted net income, thereby driving its share price to new highs

04/24/2023

ICYMI...HippoFi, Inc. (ORHB) was one of the biggest movers in the stock market last week, right after we issued our report on the company. ORHB is a fast-growing, underfollowed medtech company that offers considerable upside. Check it out here:

In what may be the best kept secret on Wall Street, emerging MedTech Firm HippoFi, Inc. (OTC:ORHB) is experiencing unprecedented sales growth. And that's just part of this innovator's story.

04/20/2023

Wall Street's best kept secret!

We have just published a new report on HippoFi, Inc. (ORHB). It is an undervalued, underfollowed medtech provider that is experiencing unprecedented sales growth. This innovative company offers major upside, based on the values placed on its lower growth peers. As word gets out, and upcoming financials are released, we would not be surprised to see aggressive accumulation.

In what may be the best kept secret on Wall Street, emerging MedTech Firm HippoFi, Inc. (OTC:ORHB) is experiencing unprecedented sales growth. And that's just part of this innovator's story.

04/13/2023

We have a new report on fast-growing consumer disc stock Charlie's Holdings (CHUC). The company is very undervalued compared to its slower-growth, larger peers--a gap we believe will narrow this year given that sales could jump by more than 60%, from $26.5M to $44M along with a potentially strong income performance. Our near term target price is 3x higher than the previous close. Check it out here: https://bit.ly/3GF18V5

03/28/2023

Good morning! We have an exciting new report our today on Camber Energy, Inc.: CEI on the NYSE. CEI may be the most diversified energy and power generation technology stock we've seen in some time. This undervalued co is set to close a merger with Viking Energy Group (VKIN) in 2H23 that serves as a catalyst to drive the combined companies' sales and CEI markedly higher. Check it out here:

The Camber Energy, Inc. (NYSE: CEI) pending merger with Viking Energy Group Inc. (OTC:VKIN) could drive CEI's market cap much higher as the combined company would emerge as one of the most diverse ene

03/22/2023

A 3/22/23 online presentation at the Emerging Growth conference could have a nice impact on innovative cancer biotech QSAM Biosciences (OTC:QSAM), where it will present updated clinical trial info. Check it out here: https://yhoo.it/3ncWGpG and check out our price target and recent report here: https://bit.ly/3kFfnRV

QSAM Biosciences, Inc. (OTCQB: QSAM) is a rare biotech. Here are ten reasons why we believe the stock is poised to enjoy significant upside ahead.

03/16/2023

Looking forward to the start of March Madness? Look no further...we just posted a great interview with the leaders of Winners Inc. (OTC:WNRS), that features the king of Vegas handicapping and its leading golf handicapper. We discuss how college sports and golf have evolved so much so fast that bettors are seeking insights and guidance from pros like Winners at an ever-increasing rate. Plus, the team gives some picks for March Madness and the Master's Tournament. Recent company news also serve as great wins for the stock. Enjoy the video---it's a lot of fun!

03/16/2023

The Silicon Valley Bank debacle has caused major downturns in the market. We identify who is really at fault, what to expect next, and how to play this phenomenon which is just beginning. https://www.youtube.com/watch?v=rjgIrR4YN2U&t=600s

03/01/2023

Clinical stage biotech company QSAM Biosciences, Inc. (OTCQB: QSAM: $4.31) is on a swift dev path that could potentially lead to an investment or acquisition by Big Pharma in 24-36 mos which is the norm for the space, given what has happened to its peers. Plus, mgmt has a deep history of FDA drug and device approvals and exits. Check out the new report on QSAM. https://bit.ly/3kFfnRV

02/21/2023

This week we answer some key questions. What has been driving the stock market higher this year, and will it continue? How will retail perform? Also, see why some very interesting moves on the ETF front has us considering a most unusual, but potentially profitable play. Are you a fan of Under Armour (NASDAQ:UA) the stock? Check out our high level views. All this and more in the latest edition of The Goldman Guide.

Goldman Small Cap Research has produced timely, actionable, research reports, blogs, and newsletters on publicly-traded emerging growth stocks, microcaps and penny stocks, along with insightful market commentary.

02/13/2023

I am sure you have all noticed the news reports of the US military shooting down unidentified flying objects, or unmanned aerial systems over the US over the past week. This could be a new trend. For our latest edition of The Goldman Guide, we dug deep and found a NASDAQ defense company that specializes in space sensing and short range air defense. Space sensing is a fast-growing segment of the military that refers to systems that monitor low earth orbit satellites, hypersonic missiles and other equipment. Seems like a great way to play this current trend as the US could ramp up and broadly deploy it. For more info check out the latest edition of the Guide where we also declare a winter for the stock market and what you should do, ahead of it.

02/09/2023

New report out today on Winners, Inc. (OTC:WNRS). It is a great time for sports gambling stocks as it is just before the Super Bowl where a record amt of Americans and funds will be bet. WNRS is our top upside play in the space and it is led by the King of Vegas gambling. Co. has a great model w/ multiple rev streams. Major growth ahead and WNRS could ultimately be a future M&A target. https://bit.ly/3JY198T

02/07/2023

Our latest quick missive provides interesting insights on the former FAANG stocks---Meta (Facebook), Amazon, Apple, Netflix, and Alphabet (Google) in side-by-side comparisons---and which one(s) we like and don't like. Plus we introduce Vanda Pharma (NASDAQ: VNDA), a biotech value play w/huge cash position and a bigtime late stage pipeline to go with its FDA approved drugs currently for sale.

02/02/2023

Hello. We have published a new report today on KwikClick (OTC:KWIK). The company's disruptive platform is already starting to change the ecommerce ecosystem. Brands get better ROI, loyalty, save $. Influencers, buyers easily become brand ambassadors and make 2-4x typical commissions, including when a follower. How? Affiliate marketers or influencers generate income when a follower clicks a direct link and if the follower chooses to become an influencer and converts a fellow follower, he/she gets paid as well. This path continues as long as that link is utilized by additional followers. Given this model, our forecasts project that exponential sales growth lies ahead

01/30/2023

Our featured stock in last week's podcast of The Goldman Guide jumped 14% and hit a new high. We have a new feature this week along with really important, overlooked info that explains why the market is rocking. Plus, we introduce an easy play in case things turn ugly in February. Listen to our short but jam-packed podcast right here! https://bit.ly/3Dot6mf

Goldman Small Cap Research has produced timely, actionable, research reports, blogs, and newsletters on publicly-traded emerging growth stocks, microcaps and penny stocks, along with insightful market commentary.

01/23/2023

Our latest podcast is up and this week we feature an under the radar NASDAQ play enjoying outsized revenue and EPS growth. Plus, see why the stock market could remain on a its current tear, unless this speed bump occurs later this week.

01/22/2023

In our latest The Goldman Guide Podcast, we feature a high growth, low valuation play that offers huge upside in an industry under major accumulation. Plus, see what sector to avoid, a sector to watch, and what stocks could impact the market during this week's earnings season.

In the latest The Goldman Guide Podcast, we feature a high growth, low valuation play that offers huge upside in an industry under major accumulation. Plus, see what sector to avoid, a sector to watch

01/18/2023

After a hiatus, we have re-introduced our popular, free weekly stock market newsletter The Goldman Guide as a podcast. For years, thousands of our subscribers read The Guide each week as it contains actionable info, data and perspectives that our founder used as a mutual fund manager and portfolio manager. Now in its podcast format with a PDF attachment full of cool info about the stock and crypto markets, it's better than ever. Click here to watch/listen and don't forget to subscribe so a link can be sent to your inbox each week. bit.ly/3QLMcIt

01/12/2023

New report on SOBR Safe (NASDAQ: SOBR). Co. set to transform alcohol detection, monitoring in multi billion $ mkts. Disruptive force w/high value SaaS model, major growth ahead. Who is the primary competitor? The installed base of nasty breathalyzers whose first introduction came almost 100 years ago! It's time they became obsolete like the milkman and SOBR could be the force behind the industry transformation with its transdermal, touch based, hygenic tech. Our price target is 4x recent closing price and still below its 52-week high.

SOBR Safe, Inc. (NASDAQ - SOBR), a developer and provider of a proprietary, cutting-edge alcohol detection offering, is on the path to replace the nearly 100-year use of breathalyzers

01/03/2023

Check out our Top 23 Predictions for 2023. We even include sports and pop culture, in addition to investing and the economy. And, we highlight why Silo Pharma $SILO could be one of NASDAQ's big winners in 1H23. Hint: Trading less than current cash p/share offers great value and big upside.

We welcome you to enjoy our Top 23 Predictions for 2023

11/17/2022

New report on SBEV w/$4 target. Overlooked, fast-growing, undervalued play set for major gains in 2023. Trades at big discount to peer group. $DEO $STZ $KDP

Splash Beverage Group, Inc. (NASDAQ - SBEV) is a fast-growing, yet undervalued beverage play that appeairs poised to enjoy major price gains in 2023.

07/09/2021

Leading blood purification therapy player Sigyn Therapeutics, Inc. (OTC - SIGY) is set to jump 40% higher following near-term milestones and on the heels of big moves higher by its peers.

04/02/2021

RocketFuel Blockchain, Inc. (OTC - RKFL) is an early mover as a global provider of one-click online payment options using Bitcoin and 40+ other cryptocurrencies---and should emerge as an M&A candidate

03/31/2021

Catalysts and milestones abound for undervalued American Premium Water Corporation (OTC - HIPH).

03/30/2021

Natural Therapeutics pioneer Herborium Group, Inc. (OTC - HBRM) is enjoying the convergence of underlying industry product demand, its proprietary products for new, widespread conditions, a big prese

03/17/2021

With its primary Pet CBD market growing 40% annually, Link Reservations, Inc. (OTC - LRSV) is set to generate meaningful share of key CBD markets in the US and Europe.